In 2016, Nikiforov et al. (JAMA Oncol 2:1023–1029, 2016) proposed replacing the term “non-invasive encapsulated follicular variant of papillary thyroid carcinoma” (FVPTC) with the term “non-invasive follicular thyroid neoplasm with papillary-like nuclear features” (NIFTP). In 2018, to avoid the misdiagnosis of papillary thyroid cancer as NIFTP, the authors proposed changes to the criteria for NIFTP classification. Some previous studies evaluated the impact of NIFTP on the risk of malignancy (ROM) in the fine-needle aspiration cytology (FNAC) diagnostic categories according to the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). However, little is known about the influence of an NIFTP diagnosis on ROM on the basis of the revised criteria. The aim of this study was to assess the influence of NIFTP on ROM using the revised diagnostic criteria. The present study included 998 thyroid nodules that were diagnosed and resected at the same medical center. All specimens with a diagnosis of cancer were reviewed to identify NIFTP according to the revised 2018 criteria. Additionally, molecular diagnostics were performed to detect the BRAF p.V600E mutation and TERT promoter mutations in all the NIFTP cases. The number of cases that met the revised criteria was determined, and the ROM was calculated in each of the FNAC diagnostic categories. Only five cases (2.3% of all papillary thyroid carcinoma diagnoses) were considered NIFTP, according to the 2018 criteria. With respect to the FNAC category, one case was a follicular neoplasm or suspicious for a follicular neoplasm (FN/SFN), three cases were suspicious for malignancy (SM), and one case was malignant (M). The ROM decreased in each of the Bethesda categories (0.7% in FN/SFN, 4.3% in SM, and 0.5% in M) when a diagnosis of NIFTP was taken into account. These reductions were not statistically significant. These data indicate that the NIFTP entity has very little impact on ROM for the diagnostic categories of the Bethesda system.

中文翻译：

---

引入新的甲状腺肿瘤类别（具有乳头状核特征的非侵入性滤泡性甲状腺肿瘤）是否可以降低Bethesda系统报告甲状腺细胞病理学诊断类别的恶性风险？

2016年，Nikiforov等人。（JAMA Oncol 2：1023–1029，2016）建议用术语“具有乳头状核特征的非侵入性滤泡性甲状腺肿瘤”（NIFTP）代替术语“非侵入性囊状甲状腺乳头状癌的滤泡性变体”（FVPTC）。 。在2018年，为了避免误诊为乳头状甲状腺癌（NIFTP），作者建议更改NIFTP分类标准。根据Bethesda报告甲状腺细胞病理学系统（TBSRTC），先前的一些研究评估了NIFTP对细针穿刺细胞学（FNAC）诊断类别中的恶性肿瘤（ROM）风险的影响。但是，根据修订后的标准，关于NIFTP诊断对ROM的影响知之甚少。这项研究的目的是使用修订后的诊断标准评估NIFTP对ROM的影响。本研究包括在同一医疗中心诊断并切除的998个甲状腺结节。根据2018年修订的标准，对所有诊断出癌症的标本进行了审查，以识别NIFTP。此外，还进行了分子诊断以检测BRAF p.V600E突变和TERT所有NIFTP病例中的启动子突变。确定符合修订标准的病例数，并在每个FNAC诊断类别中计算ROM。根据2018年的标准，只有5例病例（占所有乳头状甲状腺癌诊断的2.3％）被认为是NIFTP。就FNAC类别而言，1例为滤泡性肿瘤或可疑滤泡性肿瘤（FN / SFN），3例可疑为恶性肿瘤（SM），1例为恶性（M）。考虑到对NIFTP的诊断，每个Bethesda类别的ROM均下降（FN / SFN中的0.7％，SM中的4.3％，M中的0.5％）。这些减少没有统计学意义。这些数据表明，对于Bethesda系统的诊断类别，NIFTP实体对ROM的影响很小。